Search Results

Now showing 1 - 1 of 1

Add to my favorites
Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro
(Elsevier, 2018) Dubos-Arvis, C. (C.); Perez-Gracia, J.L. (Jose Luis); Kim, D.W; Baas, P. (P.); Lubiniecki, G.M (G. M.); Novello, S. (S.); Samkari, A. (A.); Chul-Cho, B. (B.); Su, W.C. (W. C.); Gubens, M.A. (M. A.); Han, J.Y. (J. Y.); Herbst, R.S. (Roy S.); Garon, E.B. (E. B.); Szalai, Z. (Z.); Majem-Tarruella, M. (Margarita); Ceresoli, G.L. (G. L.); Jensen, E.H. (E. H.); Forster, M. (M.); Monnet, I. (I.)
In the global, open-label, phase 2/3 study KEYNOTE-010, pembro 10 mg/kg or 2 mg/kg Q3W improved OS vs docetaxel in pts with previously treated advanced NSCLC with PD-L1 TPS ≥50% and ≥1% (coprimary analyses) at median follow-up of 13.1 mo. We present long-term results overall, in pts who completed 35 cycles (∼2 y) of pembro, and in pts who received a second course of pembro.